{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:44:31Z","timestamp":1777448671461,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>Anti\u2010epileptic drugs are commonly used in the management of neuropathic pain. Sodium valproate, however, is an anti\u2010epileptic drug that is not commonly used. We report four patients with neuropathic pain who responded very well to the initiation of low\u2010dose oral sodium valproate. Low\u2010dose sodium valproate may have a role in managing neuropathic pain, especially when other first\u2010line agents are unsuccessful or relatively contraindicated.<\/jats:p>","DOI":"10.1111\/imj.13125","type":"journal-article","created":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T01:00:56Z","timestamp":1468371656000},"page":"849-852","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The use of low\u2010dose sodium valproate in the management of neuropathic pain: illustrative case series"],"prefix":"10.1111","volume":"46","author":[{"given":"K.","family":"Pirapakaran","sequence":"first","affiliation":[{"name":"Department of Anaesthetics Royal Prince Alfred Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Pain Management Centre Royal Prince Alfred Hospital  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"key":"e_1_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.06.008"},{"key":"e_1_2_3_3_1","unstructured":"eTG. Neuropathic pain: treatment [revised June 2011]. Electronic Therepeatic Guidelines (eTG). [complete 2015 Mar 4]. [cited 2015 Aug 13]. Available from URL:http:\/\/etg.hcn.com.au\/desktop\/tgc\/nrg\/3862.htm"},{"key":"e_1_2_3_4_1","unstructured":"PBS.gov.au. Pharmaceutical Benefits Scheme \u2013 Browse by Body System. 2016. [cited 2015 Aug 13]. Available from URL:http:\/\/www.pbs.gov.au\/browse\/body\u2010system?depth=4&codes=n02bg#n02bg"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00249.x"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(98)00075-6"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216100-00003"},{"key":"e_1_2_3_8_1","first-page":"17","article-title":"Pharmacology of valproate","volume":"37","author":"Owens MJ","year":"2003","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060050-00005"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767040-00006"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci005"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.12.018"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hch007"},{"key":"e_1_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12054"},{"key":"e_1_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1980.tb131854.x"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.62.2.285"},{"key":"e_1_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(00)00266-9"},{"key":"e_1_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sc.1994.89"},{"key":"e_1_2_3_19_1","doi-asserted-by":"crossref","unstructured":"ZawabA CarmodyJ. Safe Use of Sodium Valproate.2015.[cited 2015 Dec 1]. Available from URL:http:\/\/www.australianprescriber.com\/magazine\/37\/4\/124\/7","DOI":"10.18773\/austprescr.2014.048"},{"key":"e_1_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7012.1047"},{"key":"e_1_2_3_21_1","first-page":"CD009183","article-title":"Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults","author":"Gill D","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.13125","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.13125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T12:46:17Z","timestamp":1695559577000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.13125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1111\/imj.13125"],"URL":"https:\/\/doi.org\/10.1111\/imj.13125","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"2015-11-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}